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Abstract
Background: Fatigue is a burdensome symptom in iron deficiency anemia (IDA). To capture the severity and
impact of fatigue appropriately it must be measured using validated scales. This study evaluated the content
validity and psychometric validity of the Functional Assessment of Chronic Illness Therapy - fatigue scale
(FACIT-fatigue) in IDA patients.
Methods: Qualitative patient interviews were conducted in the United States to evaluate content validity. The
psychometric properties of the FACIT-fatigue scale were investigated using data from a phase 3 clinical trial
assessing ferumoxytol in patients with a history of unsatisfactory oral iron therapy or in whom oral iron cannot
be used. The statistical analysis assessed the acceptability, reliability, validity and responsiveness of the
FACIT-fatigue scale.
Results: Qualitative interviews showed that fatigue is a central concern to IDA patients and that the FACIT-fatigue scale
sufficiently assessed this construct. Psychometric assessment demonstrated that the FACIT-fatigue scale was stable over
time (ICC = 0.87) and internally consistent (α = 0.93). The scale demonstrated convergence with other conceptually
relevant scales such as SF-36 Vitality (r = 0.74), and distinguished between known groups [i.e., treatment arms (mean
difference (95 % CI) = 3.56 (1.68, 5.43), p <0.001) and high vs. low hemoglobin groups (mean difference (95 % CI) = 5.51
(8.59, 2.44) p <0.001)]. Responsiveness was also demonstrated; significant improvements in FACIT-fatigue scale scores
corresponded with significant differences between minimal, moderate, and much improved vitality cohorts (p < 0.05).
Conclusions: This research demonstrated that the FACIT-fatigue scale has sound measurement properties and is an
appropriate and interpretable assessment of fatigue among IDA patients with various underlying conditions.
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Background
The World Health Organization (WHO) and the U.S.
Center for Disease Control and Prevention define
anemia as a hemoglobin value <12.0 g/dL in women and
<13.0 to 13.7 g/dL in men [1, 2]. According to WHO es-
timates two billion people worldwide, or 30 % of the
world’s population, are anemic [3, 4]. Iron deficiency
anemia (IDA), caused by various underlying conditions
such as abnormal uterine bleeding (AUB), post partum
bleeding, cancer and gastro-intestinal (GI) disorders, is
the leading cause of anemia worldwide; estimates sug-
gest that approximately five million people have IDA in
the United States [5].
Common symptoms of IDA include fatigue and
exercise-associated dyspnea, poor mental performance
and cold intolerance [6, 7]. Research involving anemic
cancer patients has found an increase in hemoglobin is
associated with an improvement in fatigue, which in
turn is associated with improvements in health related
quality of life (HRQL) [8, 9]. There is also evidence that
decreases in hemoglobin are related to increases in fa-
tigue duration [10].
The Functional Assessment of Chronic Illness Ther-
apy - fatigue (FACIT-fatigue) scale [11, 12] is a 13-item
instrument designed to assess fatigue/ tiredness and its
impact on daily activities and functioning in a number
of chronic diseases. The instrument includes items
such as tiredness, weakness, listlessness, lack of energy,
and the impact of these feelings on daily functioning
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(e.g., sleeping, and social activities). The FACIT-fatigue
scale (previously called the Functional Assessment of
Cancer Therapy-Fatigue (FACT-F)) was originally de-
veloped to assess cancer-related fatigue and has shown
good reliability and validity in a sample of cancer pa-
tients [12]. More recently the content validity and / or
psychometric properties of the instrument have been
established in numerous chronic conditions such as
systemic lupus erythematosus [13, 14]; rheumatoid
arthritis [15]; psoriatic arthritis [16]; chronic immune
thrombocytopenia [17] and Parkinson’s disease [18].
However, to date, the content validity and psychometric
properties have not been tested or demonstrated in
IDA. In order to use the instrument to evaluate the im-
pact of new treatments for IDA on levels of fatigue or
the impact of fatigue it is necessary to demonstrate that
the instrument is a reliable and valid measure of fatigue
for patients with IDA.
Many validation studies focus on the psychometric
properties only, without also exploring the content val-
idity of an instrument. Content validity is the extent to
which an instrument contains the relevant and import-
ant aspects of the concept of interest, and is specific to
the population of interest [19, 20]. Evidence of content
validity is required if a patient-reported outcome (PRO)
instrument is used to support a labeling claim for a
new product in the United States [19]. Evidence is ob-
tained by analyzing how the content of the instrument
relates to the construct it is intended to measure. In
order to do this, qualitative research with the popula-
tion of interest can be conducted to explore whether
the PRO instrument covers the concept of interest [20].
Therefore this paper reports research aimed to assess
both the content validity and psychometric properties
of the FACIT-fatigue scale in patients with IDA.
Throughout the paper the qualitative content validity
methods and results are presented before the psycho-
metric, quantitative, methods and results. This reflects
the fact that psychometric evidence is necessary but
not sufficient to support validity; qualitative content
validity is also required.
Methods
The qualitative content validity study was conducted as
a stand alone cross sectional study in 2013. The data
utilized for the psychometric validation analysis was
from a clinical trial that was completed before the
qualitative study was conducted (2012). As such the
study design and participants section below details each
study in turn. The inclusion / exclusion criteria for the
qualitative study were designed to reflect those used in
the clinical trial to minimize any potential differences
between the study populations.
Study design and participants
Qualitative content validation
A cross sectional, qualitative study design was developed
to gather information on the nature of fatigue and its im-
pact on HRQL experienced by IDA patients with various
underlying conditions. A two-stage concept elicitation-
cognitive debrief semi-structured interview format was de-
veloped. To reduce bias introduced when prompting for
concepts/symptoms associated with IDA, the concept
elicitation portion of the interview was conducted first. Pa-
tients were asked to describe their anemia symptoms and
the impact of these symptoms on their functioning. If fa-
tigue was not spontaneously reported during the concept
elicitation interview, the interviewer asked the patient if
they experienced fatigue before moving on to the cognitive
debrief interviews. During the cognitive debrief interview
patients completed a copy of the FACIT-fatigue scale and
were asked to “think aloud”-that is, to vocalize their inter-
pretations of and any problems with the instructions,
items, recall period, and response options. This ap-
proach permitted an evaluation of the relevance, inter-
pretability, clarity and ease of understanding of all
concepts and content of the FACIT - fatigue scale. To
keep the patient engaged throughout this process, the
interviewer was prepared with numerous probes that
fostered a conversation-like environment. Each two-
stage interview lasted approximately 60 min.
Participant recruitment was conducted through three
clinical sites in the United States. A purposive sampling
strategy was used in order to include patients with dif-
ferent underlying conditions including, AUB, post par-
tum bleeding and GI disorders. While cancer is also a
potential underlying condition of IDA, a cancer specific
population was involved in the original development of
the FACIT-fatigue and therefore not prioritized [12]. Pa-
tients were eligible to take part if: they were at least
18 years of age; they had a clinical diagnosis of IDA
[measurable hemoglobin (Hgb) range of > 7 g/dL to <
10 g /dL and transferrin saturation (TSAT) < 20 %]; they
were able to speak and read English and provide written
informed consent. Patients were ineligible if they fulfilled
any of the Phase 3 trial exclusion criteria detailed in the
Psychometric Validation Section below.
Psychometric validation
The psychometric validation was conducted on the
intent-to-treat population from a Phase 3 randomized,
placebo-controlled, double-blind trial, which examined
the impact of intravenous (IV) ferumoxytol on HRQL
compared to IV placebo in IDA patients who had a his-
tory of unsatisfactory oral iron therapy or in whom oral
iron could not be used (ClinicalTrials.gov identifier:
NCT01114139).
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The trial consisted of a Screening Period of up to
2 weeks followed by a 5-week Treatment Period. The 5-
week Treatment Period consisted of six study visits: Day
1 (Baseline, Dose 1), Week 1 (Dose 2; 2 to 8 days post-
Dose 1), and weekly thereafter up to Week 5. Patients
received a Baseline (Day 1) IV injection of either feru-
moxytol 510 mg (17 mL) or normal saline administered
as a rapid IV injection in under 1 min with a second
dose 2 to 8 days later. The FACIT-Fatigue questionnaire
was administered at Baseline and every week thereafter
to Week 5. The SF-36 and LASA questionnaires were
administered at Baseline, Week 3, and Week 5 only.
Eligible patients were males and females ≥18 years of
age with a history of IDA defined as a Hgb <10.0 g/dL
and a TSAT <20 %, who also had a history of unsatisfac-
tory oral iron therapy or in whom oral iron therapy
could not be used. Patients were not eligible for partici-
pation if they had a history of allergy to IV iron, a Hgb
≤7.0 g/dL, serum ferritin >600 ng/mL, known causes of
anemia other than iron deficiency, active infection,
hematologic malignancies, were on dialysis or had an es-
timated glomerular filtration rate <30 mL/min/1.73 m2,
or were pregnant, intended to become pregnant, or were
breastfeeding. Patients who received another investiga-
tional agent or parenteral iron therapy within 4 weeks of
screening or who had received oral iron therapy or
blood transfusion within 2 weeks prior to screening were
also excluded. A full description of the clinical trial is re-
ported elsewhere [21].
Ethics
Full Institutional Review Board (IRB) approval was ob-
tained from the Independent IRB Inc. (IIRB, Plantation,
Florida) prior to beginning recruitment of participants
for the qualitative study. The clinical trial used for the
psychometric validation analysis was conducted accord-
ing to Good Clinical Practice (GCP) guidelines and in
compliance with the ethical principles of the Declaration
of Helsinki, and was approved by the ethics committee
or institutional review board of each participating center
prior to the commencement of the study. All patients in
both studies provided written informed consent.
Measures
Three PRO measures were used: the FACIT-fatigue [12],
the Medical Outcomes Survey Short Form – 36 (SF-36)
[22], and the Linear Analogue Scale Assessments (LASA)
[23]. The FACIT-fatigue was used in both the qualitative
interviews and psychometric validation; the SF-36 and
LASA were used in the psychometric validation only.
The FACIT-fatigue scale is a 13-item patient-reported
measure of fatigue with a 7-day recall period. Items are
scored on a 0 – 4 response scale with anchors ranging
from “Not at all” to “Very much so”. To score the FACIT-
fatigue, all items are summed to create a single fatigue
score with a range from 0 to 52. Items are reverse scored
when appropriate to provide a scale in which higher scores
represent better functioning or less fatigue.
The SF-36 is a validated generic HRQL instrument
intended for use in a wide range of conditions as well as
the general population that can be self-administered. 36
items assess patient health across eight domains: bodily
pain (BP), general health perceptions (GH), mental
health (MH), physical functioning (PF), role limitations
due to emotional functioning (RE), role limitations due
to physical functioning (RP), social functioning (SF), and
vitality (VT). All items use categorical response options
(range: 2 – 6 options). From the individual subscales,
two component summary scores are generated for phys-
ical (PCS) and mental health (MCS). The first five sub-
scales (PF, RP, BP, GH, VT) produce the PCS and the
last five subscales (GH, VT, SF, RE, MH) produce the
MCS; the GH and VT subscales overlap between the
two overall components. The scores for each subscale
are converted to norm-based scores (based on 1998 US
general population), with a mean of 50 and a standard
deviation of 10. A score of 100 represents the best
health. The validity and reliability of the SF-36 has been
well established [24].
The LASA consists of three visual analogue scales
(VAS), one for each of the following domains: Energy
Level, Activities of Daily Living (ADL), and Overall
Quality of Life (QOL). Each VAS has a 7-day recall
period and consists of a 100-mm line with a left anchor
representing the worst possible score (0) and the right
anchor representing the best possible score (100). Higher
scores are indicative of better functioning / HRQL. VAS




All interviews were audio recorded and transcribed verba-
tim for qualitative analysis. Thematic analysis [26, 27] was
used for the concept elicitation interviews and content
analysis for the cognitive debrief analysis [28]. The qualita-
tive software tool MAX QDA was used to assist the ana-
lysis. Inductive coding was used to identify themes in the
concept elicitation data. In order to minimize potential
bias approximately 15 % of the transcripts were ‘double
coded’ by a second qualitative researcher. The ‘double
coded’ transcripts were reviewed by a third researcher and
any discrepancies were resolved in a meeting between all
three researchers. Saturation, which can be defined as data
adequacy or the point at which no new information is ob-
tained from additional qualitative data [29] was assessed
using saturation tables [30].
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Psychometric validation
The measurement properties of the FACIT-fatigue were
evaluated using four standard statistical assessments:
data acceptability, reliability, validity, and responsiveness.
Data acceptability was determined by examining score
distributions; acceptability is supported when observed
scores are well distributed, and mean scores are near
the scale mid-point [31]. At the item level, some items
should demonstrate a skewed distribution of response
to reflect the full range of severity of the concept is
covered. Data acceptability was assessed at Baseline and
Week 3 in case the trial inclusion criteria created a
restriction in range of scores.
Reliability was assessed by evaluating internal consistency
and test re-test reliability. Internal consistency reliability
was determined using Cronbach’s alpha (α) coefficient
[32] and item to total correlations: an α ≥ 0.80 [33, 34]
and item to total correlations ≥ 0.20 [35] were used as a
guide for determining that the FACIT-fatigue was
internally consistent. Test re-test reliability was evaluated
using an intra-class correlation coefficient (ICC). As test
re-test reliability is designed to evaluate stability over
time, this analysis was conducted on a subset of patients
with stable Hgb (<0.5 g/dL change) from Week 3 to
Week 4. An ICC of ≥ 0.80 was used as a guide to
determine test re-test reliability [36].
Validity assesses the extent to which a scale measures or
correlates with the concept it purports to measure.
Validity was determined based on correlations between
the FACIT-fatigue and other related PRO scales (SF-36
and LASA), and known groups comparisons. While
fatigue is likely to be related to all aspects of HRQL it
was hypothesized that the SF-36 VT and RP domains
and LASA Energy and ADL domains would demonstrate
the highest correlations at Baseline. Known groups
comparisons were explored based on Hgb levels (high vs.
low) and treatment arm comparisons (ferumoxytol vs.
placebo). It was hypothesized that patients with high
Hgb (Hgb > 12 g/dL) and patients in the active treatment
arm would have higher FACIT-fatigue scores (less fa-
tigue) than patients with low Hgb (Hgb < 9 g/dL) or in
the placebo arm at Week 3.
Responsiveness was determined based on change from
Baseline to Week 3 in Hgb level and SF-36 VT score.
Three Hgb groups were created: improved (≥1 g/dL),
stable (0 - <1 g/dL) and worsened (<0 g/dL). Five SF-36
VT groups were created: much improved (≥20),
moderately improved (10 - <20), minimally improved (5
- <10), stable (0 –<5) and worsened (<0). Change from
Baseline FACIT-fatigue score within each group was
assessed using repeated samples t-tests; differences
between change groups were assessed using Tukey’s
post-hoc pairwise comparisons.
All analyses were conducted on the psychometric val-
idation sample as a whole, unless otherwise specified,
using SPSS version 20.0.
Results
Patient Characteristics
Patient characteristics for the qualitative content validity
and psychometric validity samples are presented in
Table 1. The psychometric validation sample included
808 patients (intent-to-treat (ITT) population) who had
any exposure to study drug (ferumoxytol, n = 608; pla-
cebo, n = 200) and excluded 4 patients who withdrew
from the study prior to administration of study drug.
Baseline demographic and clinical characteristics, and
FACIT-fatigue scores were comparable across treatment
groups.
The content validation sample included 15 patients;
age and sex characteristics were comparable to the psy-
chometric sample and almost all key IDA sub groups
were included, with the exception of cancer. Due to the
cognitive debrief component of the qualitative analysis
patients level of education was also recorded for this




All patients spontaneously reported that their main symp-
tom experiences were “fatigue” (N = 8), “tiredness” (N = 13),
and / or “low energy” (N = 8). Other symptoms/concepts
reported included feeling weak (N = 2), being cold (N = 2),
excessive sweating (N = 2), dark circles around the eyes (N
= 2), restless (N = 1), difficulty sleeping (N = 1), dizziness
(N = 1), light-headedness (N = 1), chest pains (N = 1), nau-
sea (N = 1), muscle aches (N = 1), and hair loss (N = 1). All
Patients also reported that their symptoms had a significant
impact on daily functioning (i.e., on their home and social
activities). Six patients specifically reported that they needed
to sleep during the day, and that they viewed this problem
as a separate concept from the impact of fatigue on their
daily activities. Evaluation of data saturation established that
no new themes were added after the 4th interview. All
underlying condition subgroups spontaneously reported fa-
tigue / tiredness / low energy as a primary symptom that
impacted their HRQL and therefore further concept satur-
ation within each sub group was not deemed necessary
given the aim of this study.
Cognitive debrief
The cognitive debrief findings are summarized in Table 2.
In general, patients were able to understand and inter-
pret the FACIT-fatigue scale instructions, items, re-
sponse options, and recall period without any problems.
Further, most patients (n = 12) felt that every item on
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Table 1 Patient demographics and clinical history
Baseline characteristics Psychometric Validation Sample Qualitative Content
Validation SampleFerumoxytol (n = 608) Placebo (n = 200)
Age, years, mean (± SD) 44.8 (±13.82) 46.0 (±13.58) 41.7 (±11.3)
Female, n (%) 542 (89.1) 178 (89.0) 14 (93.3)
Race, n (%)
Asian 98 (16.1) 32 (16.0) -
Black/African American 152 (25.0) 50 (25.0) 11 (73.3)
White 340 (55.9) 111 (55.5) 4 (26.7)
Other/Multiracial 18 (3.0) 7 (3.5) -
Hgb g/dL, mean (± SD) 8.9 (±0.89) 8.8 (±0.89) -
TSAT, mean (± SD) 7.0 (12.9) 5.4 (4.9) -
Underlying condition, n (%)
AUB 260 (42.8) 84 (42.0) 11 (73.3)
Cancer 29 (4.8) 10 (5.0) -
GI disorders 173 (28.5) 58 (29.0) 1 (6.7)
Postpartum anemia 4 (0.7) 0 (0.0) 2 (13.3)
Other a 142 (23.4) 48 (24.0) 1 (6.7)
FACIT-fatigue, mean (± SD) 24.1 (11.8) 24.7 (11.3) -
SD = Standard Deviation; n = sample size; Hgb = hemoglobin; TSAT = transferrin saturation; AUB = abnormal uterine bleeding; GI = gastro-intestinal
a Other included nutritional iron deficiency, heart failure, and rheumatoid arthritis






1. I feel fatigue 14/15 14/15 “I feel tired and worn out… your body’s like - ugh…”
2. I feel weak all over 15/15 14/15 “I get really weak and drained… like someone just sucked all the energy out of
you”“I just take my time moving around, and work at getting myself built back up”
3. I feel listless (washed out) 14/15 13/15 “Feeling lifeless and you don’t want to do anything”
4. I feel tired 15/15 15/15 “I just want to sit back on the couch and do nothing -just you know lack of energy”
5. I have trouble starting things
because I am tired
15/15 15/15 “So I had to get up and force myself…So literally you have to like mentally coach,
coax myself to move forward.”
6. I have trouble finishing things
because I am tired
15/15 15/15 “I will go lay down…I say I will do it later, and I might not get back to it”
7. I have energy 15/15 15/15 “I have energy would mean, you know, I don’t feel tired, you know … I get up and
I have no problem getting started, I go through the day doing whatever I have to
do and I can go, keep going, you know… I’m not describing myself”
8. I am able to do my usual activities 15/15 15/15 “No, I’m not able to do my usual stuff”… “I need help with the yard work…”
9. I need to sleep during the day 15/15 15/15 “I’ll sleep during the day—if I have to run errands, if I’m taking my husband to an
appointment, I literally fall asleep, you know, sitting in the chair waiting—anywhere
I can take a nap, I’ll take a nap.”
10. I am too tired to eat 15/15 12/15 “I get that way sometimes. Typically if I get that way it’s because…I’m running out
of energy by that time”.
11. I need help doing my usual
activities
15/15 13/15 “…sometimes I do get help from my husband and then even times at work, like
close colleagues, I will receive assistance from them”
12. I am frustrated by being too tired
to do the things I want to do
15/15 15/15 “Yeah, right, because you know, who would think to actually get like frustrated
because you’re tired. Yeah, I am. I don’t think people realize that it’s something that
you can’t really control.”
13. I have to limit my social activity
because I am tired
15/15 15/15 “with the last date I went, I think, my attention span began to wane because I was
tired. I was like— oh, my God, you’re sitting there thinking I want to go home.”
Acaster et al. Health and Quality of Life Outcomes  (2015) 13:60 Page 5 of 10
the FACIT-fatigue scale was relevant to their experience
of IDA; item #10 (“Too tired to eat”) received the least
endorsement yet was still relevant to the majority (12/
15; 80 %). When asked whether other important con-
cepts related to their experience of IDA were not repre-
sented on the FACIT-fatigue scale, all patients reported
that the most important concepts were present.
Psychometric validity
Data acceptability
As shown in Table 3 data acceptability was supported.
At both time points all response options were endorsed,
and the mean and median item values were reasonably
comparable. Some items demonstrated evidence of floor
and ceiling affects, demonstrating the full range of fa-
tigue severity is captured.
Reliability
Internal consistency reliability was good: Cronbach’s α =
0.93. As shown in Table 3 no single item significantly
impacted the overall scale internal consistency and all
items correlated well with the overall score. Test re-test
reliability was also good with an ICC of 0.87 reported
across Weeks 3 and 4 amongst Hgb stable patients.
Validity
As hypothesized the FACIT-fatigue scale was most highly
correlated with the SF-36 VT domain (r = 0.74), and
LASA Energy (r = 0.71) and ADL (r = 0.71) domains. The
LASA QOL and SF-36 RP and SF domains all showed
similar correlations with the FACIT-Fatigue (r = 0.68, 0.67,
0.66, respectively). The SF-36 MCS and PCS domains
showed slightly lower levels of association with the
FACIT-fatigue (r = 0.62 and 0.59, respectively); all other
domains were correlated between r = 0.50 – r = 0.54 with
BP and GH providing the lowest correlations.
The validity of the FACIT-fatigue was further sup-
ported by the known groups validity data. As shown in
Table 4 patients with higher Hgb levels and patients re-
ceiving active treatment rather than placebo reported
significantly lower levels of fatigue (higher FACIT-
fatigue scores) at Week 3.
Responsiveness
As illustrated in Fig. 1, the FACIT-fatigue demonstrated
good responsiveness / ability to detect change. Changes
in the FACIT-fatigue directly reflected changes in the
SF-36 VT domain from Baseline to Week 3. All im-
proved groups demonstrated significant change from
Baseline, while the stable group also demonstrated sig-
nificant improvement from Baseline the mean FACIT-
fatigue change (4.56) was in line with the definition of
SF-36 VT stability (0 – < 5). The worsened group did
demonstrate a decline in FACIT-fatigue score, but this
did not reach statistical significance. However, Tukey’s
post-hoc paired comparisons found statistically signifi-
cant (p < 0.05) differences between all SF-36 VT change
groups.
The hemoglobin results demonstrated lower respon-
siveness as all groups showed significant improvement
in FACIT-fatigue scores from Baseline to Week 3. How-
ever, Tukey’s post hoc paired comparisons did find sig-
nificantly higher FACIT-fatigue improvement in the
improved Hgb group compared to the stable and wors-
ened groups (p < 0.05). There was no significant differ-
ence between the stable and worsened Hgb groups.
Discussion
This study assessed the qualitative content validity and
psychometric validity of the FACIT-fatigue scale in IDA
patients with various underlying conditions. The content
validity data supported fatigue as a primary symptom
among this patient population; all patients spontaneously
reported experiencing fatigue, tiredness and / or low en-
ergy. In addition, the cognitive debrief of the FACIT-
fatigue found that the majority of patients (80 –100 %)
correctly interpreted each item and felt each item to be
relevant to their experiences. The item considered least
relevant was feeling ‘too tired to eat’; this is in line with
findings from other validation studies e.g. [13] and is likely
to reflect the very severe nature of the item’s content.
However, even this severe item was still identified as ap-
propriate by the majority of patients (80 %). It should be
noted that while the qualitative study sample was a rea-
sonable reflection of the psychometric study sample, no
IDA patients with cancer as their underlying condition
were included in the qualitative sample. However, as the
FACIT was originally developed for a cancer population,
this was not considered a limitation of the study.
In line with the content validity evidence, the psycho-
metric validity analyses further supported the appropriate-
ness of the FACIT-fatigue within IDA populations. The
data acceptability results demonstrated good variability
across responses. All response options were utilized for all
items, mean and median values were similar and there
was evidence of skewed distribution for items at opposite
ends of the severity spectrum. In line with the qualitative
findings the ‘too tired to eat item’ did demonstrate greater
floor effects (high proportion of ‘not at all’ responses) at
Baseline and Week 3 than any other item. As it is import-
ant for a scale to capture the full spectrum of severity in
order to permit responsiveness to decline and improve-
ment, this should not be considered a weakness of the
FACIT-fatigue in this population.
In addition to demonstrating good data acceptability,
the descriptive item level findings also demonstrated the
responsiveness of the FACIT-fatigue scale; the direction of
severity was shown to improve from Baseline to Week 3
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Table 3 FACIT-fatigue scale acceptability and internal consistency reliability data at Baseline and Week 3















α Item - total
Correlation
I feel fatigue 0 – 4 2.71 / 3.0 (1.15) 4.3 / 29.1 0.92 0.73 0 – 4 1.61 / 1.0 (1.12) 14.9 / 5.2 0.94 0.81
I feel weak all over 0 – 4 2.26 / 2.0 (1.25) 11.4 / 17.3 0.92 0.77 0 – 4 1.23 / 1.0 (1.14) 31.1 / 3.7 0.94 0.82
I feel listless (washed out) 0 – 4 2.31 / 2.0 (1.29) 12.4 / 19.9 0.92 0.79 0 – 4 1.21 / 1.0 (1.18) 33.3 / 4.2 0.94 0.86
I feel tired 0 – 4 2.85 / 3.0 (1.12) 3.3 / 33.7 0.92 0.75 0 – 4 1.71 / 2.0 (1.15) 12.4 / 7.8 0.94 0.81
I have trouble starting things 0 – 4 2.31 / 2.0 (1.27) 11.5 / 20.2 0.92 0.81 0 – 4 1.28 / 1.0 (1.15) 29.0 / 3.3 0.94 0.85
I have trouble finishing things 0 – 4 2.30 / 2.0 (1.28) 12.3 / 19.7 0.92 0.82 0 – 4 1.34 / 1.0 (1.19) 28.5 / 3.7 0.94 0.84
I have energy 0 – 4 1.41 / 1.0 (0.98) 17.2 / 2.7 0.93 0.48 0 – 4 1.96 / 2.0 (1.03) 6.2 / 5.9 0.94 0.53
I am able to do my usual activities 0 – 4 2.14 / 2.0 (1.02) 5.0 / 9.4 0.93 0.51 0 – 4 2.51 / 3.0 (1.02) 2.2 / 16.3 0.95 0.50
I need to sleep during the day 0 – 4 2.10 / 2.0 13.9 / 17.9 0.93 0.57 0 – 4 1.32 / 1.0 (1.19) 27.4 / 5.2 0.94 0.61
I am too tired to eat 0 – 4 1.06 / 1.0 (1.31) 42.2 / 2.7 0.93 0.51 0 – 4 0.57 / 0.0 (0.91) 59.7 / 0.7 0.94 0.56
I need help doing my usual activities 0 – 4 1.14 / 1.0 (1.14) 39.2 / 3.7 0.93 0.58 0 – 4 0.79 / 0.0 (1.02) 48.9 / 1.6 0.94 0.63
I am frustrated 0 – 4 2.29 / 2.0 (1.17) 16.2 / 29.1 0.92 0.77 0 – 4 1.32 / 1.0 (1.32) 33.4 / 7.9 0.94 0.81
I have to limit my social activity because
I am tired
0 – 4 2.02 / 2.0 (1.45) 16.7 / 17.0 0.92 0.78 0 – 4 1.18 / 1.0 (1.13) 31.9 / 3.6 0.94 0.82



















as would be expected in a trial involving active treatment.
This was further supported in the specific responsiveness
analysis, which demonstrated incremental improvement
and decline in line with the SF-36 VT domain, and
hemoglobin improvement to a lesser extent. Ideally, re-
sponsiveness would have been explored using a patient
global impression of concept (fatigue) measure across time
points (e.g. asking patients to rate their global impression
of fatigue at Baseline and Week 3 and comparing the
FACIT-fatigue scores according to their global change).
However, as the psychometric validation study was con-
ducted as post-hoc analysis of trial data, rather than being
a stand-alone psychometric validation study, the use of
the SF-36 VT and hemoglobin groups as suitable anchors
of change was considered appropriate. The correlation be-
tween the FACIT-fatigue and SF-36 VT domain (r = 0.74)
supported this assumption [37]; the lower levels of respon-
siveness associated with hemoglobin as a biomarker versus
a comparable patient-reported outcome measure was not
unexpected. One interpretation of these findings is that
that hemoglobin levels alone do not fully explain the
experience of fatigue in IDA populations and therefore
demonstrate the importance of capturing the patient ex-
perience of fatigue as well as this biomarker in clinical tri-
als of IDA. However, as patients entering this study had
suppressed hemoglobin and therefore potentially sup-
pressed fatigue, these changes may reflect regression to
the mean rather than responsiveness. Further, in the case
of the stable and worsened groups, improved fatigue may
reflect placebo effects.
In relation to the reliability of the FACIT-fatigue, test-
retest reliability analysis demonstrated ‘very good’ repro-
ducibility, and the Cronbach’s alpha assessment showed
‘good’ internal consistency reliability. Furthermore, the
item-total correlations all exceeded suggested guidelines,
and the removal of any individual item had no impact on
the internal consistency. This suggests that all FACIT-
fatigue scale items relate to the global concept under as-
sessment and that no items should be removed to improve
the internal consistency of the scale.
The hypothesized convergent validity associations were
largely supported; as predicted, the SF-36 VT and LASA
Table 4 Known groups analysis: comparison of hemoglobin level groups and treatment arms at Week 3
FACIT-fatigue WK 3 Hemoglobin (Hgb) Severity Treatment Arm
High Hgb (>12 g/dL) Low Hgb (< = 9 g/dL) Ferumoxytol Placebo
N 102 106 555 183
Mean 35.96 30.45 35.78 32.22
SD 10.82 11.64 11.31 10.92
Mean Difference (95 % CI) -5.51 (-8.59, -2.44) - 3.56 (-1.68, -5.43)
P value <0.001 <0.001
Fig. 1 FACIT-fatigue responsiveness: change from Baseline to Week 3 by hemoglobin and SF-36 Vitality domain. Hemoglobin groups:
improved (≥1 g/dL), stable (0 - <1 g/dL) and worsened (<0 g/dL). SF-36 VT groups: much improved (≥20), moderately improved (10 - <20),
minimally improved (5 - <10), stable (0 – <5) and worsened (<0)*** Change from Baseline to Week 3 p < 0.001 Error bars represent 95 %
confidence intervals (1.96 x standard error)
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Energy and ADL items were the most strongly correlated
constructs to the FACIT-fatigue scale. However, while the
SF-36 RP was also strongly correlated to the FACIT-
fatigue (as predicted), this was also true of the SF-36 SF
and LASA QOL domains. Thus, while correlational con-
vergence between fatigue and conceptually related PRO
constructs was seen, all aspects of HRQL were associated
with fatigue to a moderate extent. Given the conceptual
link between social and mental functioning with fatigue,
these results do not challenge the evidence of good con-
vergent validity. Finally, known groups validity was also
supported. At Week 3 patients receiving ferumoxytol and
those with higher Hgb levels reported lower levels of fa-
tigue than those receiving placebo or with lower Hgb
levels. Again, known groups validity would have been best
conducted based on a more concrete assessment of known
fatigue, such as a patient global impression of concept (i.e.
patients who categorized their fatigue as mild, moderate or
severe). However, given the statistically significant group
differences reported, based on a biomarker and treatment
arm after only 3 treatment doses, these results could be
considered a conservative assessment of the FACIT-fatigue
scales ability to distinguish between groups.
As suggested above, a potential limitation of this study
was the post hoc nature of the psychometric analysis based
on clinical trial data. This meant the analyses were con-
fined to the instruments collected as part of the clinical
trials and were not included a priori for the purposes of
conducting a validation study. Thus, while the available
measures were considered appropriate, the responsiveness
and known groups analysis for example may have been
improved with the inclusion of a patient global impression
of concept item. However, clinical trial data is frequently
used to provide evidence, or lack thereof, of the measure-
ment properties of new or existing instruments in a par-
ticular population [38-40]. Replication of these findings in
a prospective validation specific study could still add to
the body of evidence supporting the use of the FACIT-
fatigue in an IDA population.
The present study suggests the FACIT-fatigue is a con-
ceptually relevant scale to be used in IDA populations,
and that its content is clear and meaningful to patients.
Further, the psychometric evidence supports the measure-
ment properties of the FACIT-fatigue in IDA populations
demonstrating stability of scores over time, internal
consistency of items, evidence that it does measure the
concept it purports to measure, and sensitivity to detect
change. These combined findings support the use of the
FACIT-fatigue in IDA populations and further highlight
the value of capturing patient-reported outcomes as well
as biomarkers in research and clinical settings.
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